Abstract 621P
Background
Consensus molecular subtypes (CMSs) are used to classify metastatic colorectal cancer (mCRC) based on gene expression patterns and may provide insights into the biology of the disease and guide treatment decisions. Here, we describe the systemic proteome of CMSs from patients with RAS wild-type (wt) mCRC receiving fluorouracil and folinic acid with or without panitumumab (Pmab) after Pmab + mFOLFOX6 induction within the randomized phase II PanaMa trial.
Methods
Serum samples were collected at baseline (prior to first cycle of chemotherapy) from 271 RAS wt mCRC patients within the PanaMa trial, and the CMS classification was determined by RNA sequencing of the primary tumor. The systemic proteome was analyzed from serum using liquid chromatography-mass spectrometry. Differential protein abundance analysis was performed to identify potential biomarkers and pathways associated with CMSs.
Results
A total of 6 differentially abundant proteins (DAPs) were identified among CMS subtypes. For CMS1, no significant DAPs were detected. CMS2 showed significant downregulation of C-reactive protein (CRP, 1.47-fold decrease; P=0.011). CMS3 showed significant upregulation of immunoglobulin-related proteins. In contrast to CMS2, CMS4 presented significant downregulation of peptidoglycan recognition protein 2 (PGLYRP2, 0.72-fold decrease; P=0.027) and upregulation of CRP (1.46-fold increase; P=0.027) and SERPINA1 (0.65-fold increase; P=0.048) and SERPINA3 (0.66-fold increase; P=0.048).
Conclusions
The identification of CMS-specific proteomic signatures helps elucidate the systemic setting of CMS-based tumor classification and ultimately may help inform the development of personalized treatment strategies for patients with mCRC.
Clinical trial identification
NCT01991873.
Editorial acknowledgement
Legal entity responsible for the study
AIO-Studien-gGmbH.
Funding
The legal funder (sponsor) of the trial was the AIO Studien gGmbH, Berlin, Germany. Amgen Inc (Thousand Oaks, CA, USA) supported the trial with study medication and a research grant to the AIO Studien gGmbH.
Disclosure
A. Ballhausen: Financial Interests, Personal, Stocks or ownership: BioNTech SE; Financial Interests, Personal, Training: Amgen; Financial Interests, Institutional, Research Grant: Amgen. A. Stahler: Financial Interests, Personal, Funding: Roche, Servier, Taiho Pharmaceutical; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb/Pfizer, Novocure; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Amgen, Roche, Lilly, Pfizer. M. Karthaus: Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Amgen; Financial Interests, Personal, Advisory Role: Amgen. U. Graeven: Financial Interests, Personal, Stocks/Shares: BioNTech SE; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim, Amgen, AstraZeneca, Bristol Myers Squibb, MSD Oncology, Sanofi Aventis GmbH, Fujifilm, Novartis, Celltrion; Financial Interests, Personal, Advisory Role: Amgen, MSD Oncology; Financial Interests, Institutional, Research Funding: Ipsen, MacroGenics; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Boehringer Ingelheim, GSK. A.H.S. Alig: Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck, Bristol Myers Squibb GmbH & Co. KG; Financial Interests, Personal, Other, Honoraria: MSD. E. Goekkurt: Financial Interests, Personal, Advisory Role: MSD, Bristol Myers Squibb, AstraZeneca/Daiichi Sankyo, Pfizer. A. Kurreck: Financial Interests, Personal, Other, Honoraria: Taiho Pharmaceutical, Amgen, Servier; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Medac, Amgen, Servier. S. Kasper-Virchow: Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb, MSD Oncology, AstraZeneca, Merck Serono, Amgen, Roche, Servier, Amgen, Lilly, Sanofi/Aventis, Novartis, Pierre Fabre; Financial Interests, Personal, Advisory Role: Roche, Merck Serono, Amgen, MSD Oncology, Sanofi, Bristol Myers Squibb, Lilly, Servier, AstraZeneca, Janssen-Cilag, Novartis, Pierre Fabre, Incyte; Financial Interests, Personal, Research Funding: Merck Serono, Bristol Myers Squibb, Celgene, Lilly, Servier, Roche/Genentech; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck Serono, Lilly, Amgen, Sanofi, Roche, Pierre Fabre, Bristol Myers Squibb. V. Heinemann: Financial Interests, Personal, Advisory Board, Honoraria: Roche, Amgen, Sanofi, Merck, Servier, Pfizer, Pierre Fabre, AstraZeneca, MSD, Seagen; Financial Interests, Personal, Advisory Role: Merck, Amgen, Roche, MSD, Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre, TERUMO, GSK, Servier/Pfizer, AstraZeneca, OncoSil, Nordic Bioscience; Financial Interests, Institutional, Research Funding: Merck, Amgen, Roche; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Merck. S. Stintzing: Financial Interests, Personal, Advisory Board: Amgen, Bayer, Lilly, Pierre Fabre, Merck KgaA, MSD, Roche, Sanofi, Taiho, Takeda; Financial Interests, Personal, Invited Speaker: Leo Pharma, AstraZeneca; Financial Interests, Institutional, Research Grant: Merck KGaA, Pierre Fabre, Roche. T. Trarbach: Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Ipsen, Takeda, OMT, AbbVie, Novartis, MSD, Sanofi/Aventis, Amgen, Johnson & Johnson/Janssen; Financial Interests, Personal, Research Funding: Amgen. D.P. Modest: Financial Interests, Personal, Invited Speaker: Amgen, Servier, Merck, Onkowissen, MSD, Bristol Myers Squibb, AstraZeneca, Pierre Fabre, Lilly, Cureteq, GSK, Seagen, Medison, COR2ED, JE, 21up; Financial Interests, Personal, Advisory Board: Amgen, Servier, Merck, MSD, Bristol Myers Squibb, Incyte, Takeda, G1, Onkowissen, Pierre Fabre, AstraZeneca; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Coordinating PI: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
548P - Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Presenter: Carolina Trabulo
Session: Poster session 10
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
568P - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Presenter: Faiz Jabbar
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10